Historical Valuation
Mangoceuticals Inc (MGRX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Mangoceuticals Inc (MGRX) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：0.99
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Mangoceuticals Inc (MGRX) has a current Price-to-Book (P/B) ratio of 0.75. Compared to its 3-year average P/B ratio of 2.76 , the current P/B ratio is approximately -72.75% higher. Relative to its 5-year average P/B ratio of 2.76, the current P/B ratio is about -72.75% higher. Mangoceuticals Inc (MGRX) has a Forward Free Cash Flow (FCF) yield of approximately -44.94%. Compared to its 3-year average FCF yield of -56.10%, the current FCF yield is approximately -19.89% lower. Relative to its 5-year average FCF yield of -56.10% , the current FCF yield is about -19.89% lower.
P/B
Median3y
2.76
Median5y
2.76
FCF Yield
Median3y
-56.10
Median5y
-56.10
Competitors Valuation Multiple
AI Analysis for MGRX
The average P/S ratio for MGRX competitors is 0.00, providing a benchmark for relative valuation. Mangoceuticals Inc Corp (MGRX.O) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of -36.83%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for MGRX
1Y
3Y
5Y
Market capitalization of MGRX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of MGRX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is MGRX currently overvalued or undervalued?
Mangoceuticals Inc (MGRX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Mangoceuticals Inc (MGRX) is between to according to relative valuation methord.
What is Mangoceuticals Inc (MGRX) fair value?
MGRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Mangoceuticals Inc (MGRX) is between to according to relative valuation methord.
How does MGRX's valuation metrics compare to the industry average?
The average P/S ratio for MGRX's competitors is 0.00, providing a benchmark for relative valuation. Mangoceuticals Inc Corp (MGRX) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of -36.83%, this premium appears unsustainable.
What is the current P/B ratio for Mangoceuticals Inc (MGRX) as of Jan 10 2026?
As of Jan 10 2026, Mangoceuticals Inc (MGRX) has a P/B ratio of 0.75. This indicates that the market values MGRX at 0.75 times its book value.
What is the current FCF Yield for Mangoceuticals Inc (MGRX) as of Jan 10 2026?
As of Jan 10 2026, Mangoceuticals Inc (MGRX) has a FCF Yield of -44.94%. This means that for every dollar of Mangoceuticals Inc’s market capitalization, the company generates -44.94 cents in free cash flow.
What is the current Forward P/E ratio for Mangoceuticals Inc (MGRX) as of Jan 10 2026?
As of Jan 10 2026, Mangoceuticals Inc (MGRX) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of Mangoceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Mangoceuticals Inc (MGRX) as of Jan 10 2026?
As of Jan 10 2026, Mangoceuticals Inc (MGRX) has a Forward P/S ratio of 0.00. This means the market is valuing MGRX at $0.00 for every dollar of expected revenue over the next 12 months.